These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23084902)

  • 1. Exploration of cathepsin S inhibitors characterized by a triazole P1-P2 amide replacement.
    Moss N; Xiong Z; Burke M; Cogan D; Gao DA; Haverty K; Heim-Riether A; Hickey ER; Nagaraja R; Netherton M; O'Shea K; Ramsden P; Schwartz R; Shih DT; Ward Y; Young E; Zhang Q
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7189-93. PubMed ID: 23084902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.
    Chatterjee AK; Liu H; Tully DC; Guo J; Epple R; Russo R; Williams J; Roberts M; Tuntland T; Chang J; Gordon P; Hollenbeck T; Tumanut C; Li J; Harris JL
    Bioorg Med Chem Lett; 2007 May; 17(10):2899-903. PubMed ID: 17382545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method.
    Patterson AW; Wood WJ; Hornsby M; Lesley S; Spraggon G; Ellman JA
    J Med Chem; 2006 Oct; 49(21):6298-307. PubMed ID: 17034136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
    Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
    Tully DC; Liu H; Chatterjee AK; Alper PB; Epple R; Williams JA; Roberts MJ; Woodmansee DH; Masick BT; Tumanut C; Li J; Spraggon G; Hornsby M; Chang J; Tuntland T; Hollenbeck T; Gordon P; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5112-7. PubMed ID: 16876402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazole-based cathepsin S inhibitors with improved cellular potency.
    Wei J; Pio BA; Cai H; Meduna SP; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5525-8. PubMed ID: 17822900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.
    Black WC; Bayly CI; Davis DE; Desmarais S; Falgueyret JP; Léger S; Li CS; Massé F; McKay DJ; Palmer JT; Percival MD; Robichaud J; Tsou N; Zamboni R
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4741-4. PubMed ID: 16154747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
    Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.
    Kerns JK; Nie H; Bondinell W; Widdowson KL; Yamashita DS; Rahman A; Podolin PL; Carpenter DC; Jin Q; Riflade B; Dong X; Nevins N; Keller PM; Mitchell L; Tomaszek T
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4409-15. PubMed ID: 21733692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
    Naud J; Lemke C; Goudreau N; Beaulieu E; White PD; Llinàs-Brunet M; Forgione P
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3400-4. PubMed ID: 18448339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors.
    Cai J; Baugh M; Black D; Long C; Jonathan Bennett D; Dempster M; Fradera X; Gillespie J; Andrews F; Boucharens S; Bruin J; Cameron KS; Cumming I; Hamilton W; Jones PS; Kaptein A; Kinghorn E; Maidment M; Martin I; Mitchell A; Rankovic Z; Robinson J; Scullion P; Uitdehaag JC; Vink P; Westwood P; van Zeeland M; van Berkom L; Bastiani M; Meulemans T
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4350-4. PubMed ID: 20598883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.
    Boros EE; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Paulick MG; Shewchuk LM; Thompson JB; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3425-9. PubMed ID: 15177446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
    Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
    J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
    Ameriks MK; Axe FU; Bembenek SD; Edwards JP; Gu Y; Karlsson L; Randal M; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6131-4. PubMed ID: 19773165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S.
    Galibert M; Wartenberg M; Lecaille F; Saidi A; Mavel S; Joulin-Giet A; Korkmaz B; Brömme D; Aucagne V; Delmas AF; Lalmanach G
    Eur J Med Chem; 2018 Jan; 144():201-210. PubMed ID: 29272750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of the P1 SAR of aldehyde cathepsin K inhibitors.
    Catalano JG; Deaton DN; Furfine ES; Hassell AM; McFadyen RB; Miller AB; Miller LR; Shewchuk LM; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2004 Jan; 14(1):275-8. PubMed ID: 14684342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
    Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of selective Cathepsin inhibitors.
    Bethel PA; Gerhardt S; Jones EV; Kenny PW; Karoutchi GI; Morley AD; Oldham K; Rankine N; Augustin M; Krapp S; Simader H; Steinbacher S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4622-5. PubMed ID: 19616430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors. Part 2: Modification of P3, P4, and P5 regions.
    Wiener JJ; Wickboldt AT; Wiener DK; Lee-Dutra A; Edwards JP; Karlsson L; Nguyen S; Sun S; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2375-8. PubMed ID: 20171097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors.
    Tully DC; Liu H; Chatterjee AK; Alper PB; Williams JA; Roberts MJ; Mutnick D; Woodmansee DH; Hollenbeck T; Gordon P; Chang J; Tuntland T; Tumanut C; Li J; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5107-11. PubMed ID: 16876407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.